港股异动 | 微创医疗(00853)早盘跌超5% 全年亏损预计收窄58% 小摩看好其26年实现扭亏为盈

智通财经网03-10

微创医疗(00853)早盘跌超5%，截至发稿，跌5.54%，报7.67港元，成交额1.57亿港元。消息面上，微创医疗发布盈警，预计2024年度净亏损不超过2.75亿美元，同比收窄超过58%。主要因收入录得近10%的增长，特别是出海业务收入大幅增长约80%；集团持续推进落实资源聚焦，运营效率获得提升，经营费用占收入比率下降约28个百分点；及年内完成数家非核心业务的出售，带来正向收益。小摩发表研报称，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518250440?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-10 11:13","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2518250440","market":"sg","top_or_hot":-1,"title":"港股异动 | 微创医疗(00853)早盘跌超5% 全年亏损预计收窄58% 小摩看好其26年实现扭亏为盈","media":"智通财经网","content":"<div>\n<p>微创医疗(00853)早盘跌超5%，截至发稿，跌5.54%，报7.67港元，成交额1.57亿港元。消息面上，微创医疗发布盈警，预计2024年度净亏损不超过2.75亿美元，同比收窄超过58%。主要因收入录得近10%的增长，特别是出海业务收入大幅增长约80%；集团持续推进落实资源聚焦，运营效率获得提升，经营费用占收入比率下降约28个百分点；及年内完成数家非核心业务的出售，带来正向收益。小摩发表研报称，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-10/doc-inepcsmq0865504.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 微创医疗(00853)早盘跌超5% 全年亏损预计收窄58% 小摩看好其26年实现扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 微创医疗(00853)早盘跌超5% 全年亏损预计收窄58% 小摩看好其26年实现扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-10 11:13 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-10/doc-inepcsmq0865504.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>微创医疗(00853)早盘跌超5%，截至发稿，跌5.54%，报7.67港元，成交额1.57亿港元。消息面上，微创医疗发布盈警，预计2024年度净亏损不超过2.75亿美元，同比收窄超过58%。主要因收入录得近10%的增长，特别是出海业务收入大幅增长约80%；集团持续推进落实资源聚焦，运营效率获得提升，经营费用占收入比率下降约28个百分点；及年内完成数家非核心业务的出售，带来正向收益。小摩发表研报称，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-10/doc-inepcsmq0865504.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-10/doc-inepcsmq0865504.shtml","article_id":"2518250440","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518250440","pubTimestamp":1741576380,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"微创医疗早盘跌超5%，截至发稿，跌5.54%，报7.67港元，成交额1.57亿港元。消息面上，微创医疗发布盈警，预计2024年度净亏损不超过2.75亿美元，同比收窄超过58%。小摩发表研报称，对微创医疗持积极看法，形容在中小型医疗技术领域中，集团是多元化本地领导者，具有强大的创新能力、海外市场扩张，并且预计至2026年可扭亏为盈；又指集团仍然是该行在SMID医疗技术领域的首选。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU0238689110.USD":"贝莱德环球动力股票基金","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","00853":"微创医疗","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK1585":"昨日强势股","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4516":"特朗普概念","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0106831901.USD":"贝莱德世界金融基金A2","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","BK4534":"瑞士信贷持仓","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4588":"碎股","BK4550":"红杉资本持仓","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU1917777945.USD":"安联专题基金Cl AT Acc"},"translate_title":"Changes in Hong Kong stocks MicroPort Medical (00853) fell more than 5% in early trading, full-year losses are expected to narrow by 58%, JPMorgan is optimistic about its turnaround in 26 years","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1},"content_text":"微创医疗(00853)早盘跌超5%，截至发稿，跌5.54%，报7.67港元，成交额1.57亿港元。消息面上，微创医疗发布盈警，预计2024年度净亏损不超过2.75亿美元，同比收窄超过58%。主要因收入录得近10%的增长，特别是出海业务收入大幅增长约80%；集团持续推进落实资源聚焦，运营效率获得提升，经营费用占收入比率下降约28个百分点；及年内完成数家非核心业务的出售，带来正向收益。小摩发表研报称，对微创医疗持积极看法，形容在中小型医疗技术领域(SMID)中，集团是多元化本地领导者，具有强大的创新能力、海外市场扩张，并且预计至2026年可扭亏为盈；又指集团仍然是该行在SMID医疗技术领域的首选。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518250440"}